6533b854fe1ef96bd12ae519

RESEARCH PRODUCT

Disease activity states, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept

S. VerazzaS. DavìA. ConsolaroA. InsalacoV. GerloniR. CimazF. ZulianS. PastoreF. CoronaG. ContiP. BaroneM. CattaliniE. CortisL. BredaA. N. OlivieriA. CivinoR. PoddaD. RiganteF. La TorreG. D'angeloM. JoriniR. GallizziM. C. MaggioR. ConsoliniA. De FantiM. G. AlpigianiA. MartiniA. Ravelli

subject

Settore MED/38 - Pediatria Generale E Specialisticabiologic medications etanerceptjuvenile idiopathic arthritis

description

The advent of biologic medications has increased considerably the potential for treatment benefit in juvenile idiopathic arthritis (JIA), with clinical remission being now achievable in a substantial proportion of patients. However, there is a need of data from the real world of clinical practice to evaluate thoroughly the efficacy and safety profile of the biologic agents currently approved.

yearjournalcountryeditionlanguage
2017-01-01
http://hdl.handle.net/10447/390091